Merck Launches Phase 3 Trial for OHTUVAYRE to Prevent COPD Exacerbations

Merck's decision to advance OHTUVAYRE into a Phase 3 exacerbation trial signals an imminent scale-up obligation for clinical supply chains and manufacturing operations already supporting the approved maintenance indication. For plant heads and QA directors managing respiratory drug programs, the expansion of a post-approval asset into a new efficacy endpoint introduces parallel demands: sustaining commercial batch release while provisioning investigational product under 21 CFR Part 211 and applicable GMP frameworks.

OHTUVAYRE (ensifentrine), a dual PDE3/PDE4 inhibitor approved by the FDA in June 2024 for maintenance treatment of COPD, is now being evaluated for its potential to reduce disease exacerbations, a distinct and clinically harder endpoint than bronchodilation. The Phase 3 trial represents Merck's effort to broaden the clinical evidence base for the asset, which it acquired through its $680 million purchase of Verona Pharma in 2024.

For regulatory affairs leads, the trial design will carry weight beyond the COPD indication. Exacerbation reduction trials generate long-duration exposure data that can inform post-market safety commitments, label negotiations, and risk management strategy. Depending on protocol design, the dataset may also intersect with ICH E6(R3) expectations around data integrity and site oversight, areas under active FDA scrutiny in respiratory therapeutic programs.

On the supply side, nebulized formulations like OHTUVAYRE present specific clinical packaging and cold-chain considerations that differ materially from dry-powder or metered-dose inhaler formats. QA teams supporting investigational site networks will need to confirm that comparability protocols between commercial and clinical batches are documented and defensible ahead of any interim analysis or regulatory submission.

The exacerbation trial outcome will serve as a measurable checkpoint for Merck's broader respiratory franchise strategy, with label expansion contingent on demonstrating statistically significant reduction in moderate-to-severe COPD exacerbation rates across the trial population.

Source: Media4Growth via Indian Pharma Post, 3 November 2026.